Last reviewed · How we verify
Intraviteal Ranibizumab 0.5mg — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Intraviteal Ranibizumab 0.5mg (Intraviteal Ranibizumab 0.5mg) — Nagoya City University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intraviteal Ranibizumab 0.5mg TARGET | Intraviteal Ranibizumab 0.5mg | Nagoya City University | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intraviteal Ranibizumab 0.5mg CI watch — RSS
- Intraviteal Ranibizumab 0.5mg CI watch — Atom
- Intraviteal Ranibizumab 0.5mg CI watch — JSON
- Intraviteal Ranibizumab 0.5mg alone — RSS
Cite this brief
Drug Landscape (2026). Intraviteal Ranibizumab 0.5mg — Competitive Intelligence Brief. https://druglandscape.com/ci/intraviteal-ranibizumab-0-5mg. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab